Janus kinase

By Targets:	JAK (19) Apoptosis (1) CDK (1) FLT3 (1) Isotope-Labeled Compounds (1) Microtubule/Tubulin (1) STAT (3)
By Research Areas:	Cancer (8) Infection (1) Inflammation/Immunology (12)

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Inflammation/Immunology Cancer
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .

HY-148785

Nimucitinib

JAK Others

Nimucitinib is a Janus kinase (JAK) inhibitor .
HY-148791

Pumecitinib

PG-011
JAK Inflammation/Immunology Cancer

Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity .
HY-101976

JAK3-IN-6

JAK Inflammation/Immunology

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.
HY-148798

Rovadicitinib

JAK Cancer

Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC₅₀ value <20 nM. Rovadicitinib also exhibits anti-inflammatory activity .

Nimucitinib	JAK	Others
Nimucitinib is a Janus kinase (JAK) inhibitor .

Pumecitinib PG-011	JAK	Inflammation/Immunology Cancer
Pumecitinib is a **Janus kinase (JAK**) inhibitor with anti-inflammatory activity .

JAK3-IN-6	JAK	Inflammation/Immunology
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

Rovadicitinib	JAK	Cancer
Rovadicitinib is a **Janus kinase (JAK) inhibitor with an IC₅₀** value <20 nM. Rovadicitinib also exhibits anti-inflammatory activity .

HY-156621

Lepzacitinib	JAK	Inflammation/Immunology
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs .

HY-132849

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .

HY-161259

JAK-IN-36	JAK	Inflammation/Immunology
JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1) with a IC₅₀ value of 2.2 nM. JAK-IN-36 can be used in the study of autoimmune diseases .

HY-151258

TK4g	JAK	Cancer
TK4g is a **Janus kinase (JAK) inhibitor with the IC₅₀** values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research .

HY-151259

TK4b	JAK	Cancer
TK4b is a **Janus kinase (JAK) inhibitor with the IC₅₀** values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively. TK4b can be used in lymphoid-derived diseases and leukemia cancer research .

HY-156423

Tubulin/JAK2-IN-1	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-112708

Brepocitinib 2 Publications Verification PF-06700841	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-112708A

Brepocitinib P-Tosylate 2 Publications Verification PF-06700841 P-Tosylate	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-125019

iJak-381	JAK STAT	Inflammation/Immunology
iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .

HY-149257

HAT-SIL-TG-1&AT	JAK STAT	Cancer
HAT-SIL-TG-1&AT is a **Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5** under hypoxic conditions .

HY-19569

Upadacitinib Maximum Cited Publications 7 Publications Verification ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-19569R

Upadacitinib (Standard) ABT-494 (Standard)	JAK	Others
Upadacitinib (Standard) is the analytical standard of Upadacitinib. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-15163

Zotiraciclib TG02; SB1317	JAK CDK FLT3	Cancer
Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC₅₀ values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .

HY-W727879

Upadacitinib-15N,d2 ABT-494-¹⁵N,d₂	Isotope-Labeled Compounds	Others
Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	423 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 423 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

423 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 423 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2521

Tetramethylcurcumin FLLL31	other families Classification of Application Fields Source classification Phenols Plants Disease Research Fields Inflammation/Immunology	STAT Apoptosis
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .

Species:	Human (6)
Tag:	His (4) Tag Free (1) GST (1)
Source:	Sf9 insect cells (2) P. pastoris (2) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P7989

	Janus kinase 2/JAK2 Protein, Human (His) JAK2, Janus kinase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P701102

	Janus kinase 2/JAK2 Protein, Human (381aa, His) JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating kinase 2; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; JTK 10; JTK10; kinase Jak2; OTTHUMP00000043260; THCYT3; Tyrosine protein kinase JAK2; Tyrosine-protein kinase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P702720

Janus kinase 2/JAK2 Protein, Human (sf9)

JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3
Human Sf9 insect cells

HY-P702721

	JAK3 Protein, Human (sf9, GST) JAK3; Janus kinase 3; tyrosine-protein kinase JAK3; JAK 3; JAK3_HUMAN; JAKL; L JAK; leukocyte Janus kinase; LJAK; tyrosine protein kinase JAK3; Janus kinase 3 (a protein tyrosine kinase, leukocyte); JAK-3; L-JAK	Human	Sf9 insect cells

HY-P700583

	JAK1 Protein, Human (P. pastoris, His) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	Human	P. pastoris
	JAK1 protein is a non-receptor tyrosine kinase that plays a crucial role in IFN-α/β/γ signaling and serves as a kinase partner for IL-2 and IL-10 receptors. It cooperates with the type I interferon receptor IFNAR2 to phosphorylate and activate IFNAR2 upon interferon binding to IFNAR1-IFNAR2. JAK1 Protein, Human (P. pastoris, His) is the recombinant human-derived JAK1 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of JAK1 Protein, Human (P. pastoris, His) is 305 a.a., with molecular weight of 36.9 kDa.

HY-P71785

	SOCS1 Protein, Human (P.pastoris, His) CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3	Human	P. pastoris
	The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag. The total length of SOCS1 Protein, Human (P.pastoris, His) is 211 a.a., with molecular weight of ~25.6 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W727879

Upadacitinib-15N,d2
Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

Cat. No.	Product Name	Application	Reactivity

HY-P82721

JAK3 Antibody (YA2466)

JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte Janus kinase; L-JAK
WB, ICC/IF Human

HY-P80727

JAK2 Antibody (YA330) JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
JAK2 Antibody (YA330) is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to JAK2. It can be used for WB assays with tag free, in the background of Human, Mouse.

HY-P80829

Phospho-JAK2 (Tyr1007/1008) Antibody JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
Phospho-JAK2 (Tyr1007/1008) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 131 kDa, targeting to Phospho-JAK2 (Tyr1007/1008). It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80726

JAK1 Antibody (YA722) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
JAK1 Antibody (YA722) is a non-conjugated and Mouse origined monoclonal antibody about 133 kDa, targeting to JAK1 (8B8). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Rat.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies